{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00021449", "CSN": null, "TRF": "ORD_1398056_01", "MRN": "47784703", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1147872", "clinicalId": "1149242", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1398056_01", "SampleName": "US1343001.01", "Version": "0", "Sample": {"FM_Id": "ORD_1398056_01", "SampleId": "US1343001.01", "BlockId": "S111-21811F", "TRFNumber": "ORD_1398056_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_06_27", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "20", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-99722", "MRN": "47784703", "FullName": "\u5f6d\u96c5\u5a77", "FirstName": "Ya_Ting", "LastName": "Peng", "SubmittedDiagnosis": "Atypical meningioma, Meninges", "Gender": "Female", "DOB": "1987_08_19", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_06_07", "ReceivedDate": "2022-07-07 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Meningioma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "9", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "AXIN1", "isVUS": "true", "variantName": "V849I"}, {"geneName": "BRIP1", "isVUS": "true", "variantName": "G481D"}, {"geneName": "CUL4A", "isVUS": "true", "variantName": "T66M"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "E457del"}, {"geneName": "DOT1L", "isVUS": "true", "variantName": "V467A"}, {"geneName": "MYD88", "isVUS": "true", "variantName": "C229S"}, {"geneName": "TIPARP", "isVUS": "true", "variantName": "R133L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). The reported incidence of MSI in meningioma has varied significantly between studies (Pykett et al., 1994; 7987826, Alvino et al., 2000; 11045018, Simon et al., 1996; 8875241, Zhu et al., 1996; 8622857, Pecina_Slaus et al., 2016; 27630299, Chen et al., 2012; 22930430, Pecina_Slaus et al., 2017; 28705114). The prognostic significance of MSI in meningioma is unknown (PubMed, Aug 2021). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Meningioma harbors a median TMB of 1.8 mutations per megabase (muts/Mb), and 0.9% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Grade 2 or 3 meningiomas have been associated with a higher mutation rate than Grade 1 meningiomas; meningiomas were reported to have a smaller number of somatic alterations relative to other tumor types (Brastianos et al., 2013; 23334667). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "1", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "2", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "3", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "4", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "5", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "6", "ReferenceId": "7987826", "FullCitation": "Pykett MJ, et al. Cancer Res. (1994) pmid: 7987826", "Include": "true"}, {"number": "7", "ReferenceId": "11045018", "FullCitation": "Alvino E, et al. Neurol. Res. (2000) pmid: 11045018", "Include": "true"}, {"number": "8", "ReferenceId": "8875241", "FullCitation": "Simon M, et al. Genes Chromosomes Cancer (1996) pmid: 8875241", "Include": "true"}, {"number": "9", "ReferenceId": "8622857", "FullCitation": "Zhu J, et al. Oncogene (1996) pmid: 8622857", "Include": "true"}, {"number": "10", "ReferenceId": "27630299", "FullCitation": "Pe\u0107ina_\u0160laus N, et al. Anticancer Res. (2016) pmid: 27630299", "Include": "true"}, {"number": "11", "ReferenceId": "22930430", "FullCitation": "Chen MN, et al. Genet. Mol. Res. (2012) pmid: 22930430", "Include": "true"}, {"number": "12", "ReferenceId": "28705114", "FullCitation": "Pe\u0107ina_\u0160laus N, et al. Tumour Biol. (2017) pmid: 28705114", "Include": "true"}, {"number": "13", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "14", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "15", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "16", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "17", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "18", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "19", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "20", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "21", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "22", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "23", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "24", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "25", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "26", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "27", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "28", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "29", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "30", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "31", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "32", "ReferenceId": "23334667", "FullCitation": "Brastianos PK, et al. Nat. Genet. (2013) pmid: 23334667", "Include": "true"}, {"number": "33", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "34", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "35", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "36", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "37", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "38", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "39", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "40", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "41", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "42", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "43", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "44", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_07_05 20:39:59", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "891x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": {"comment": {"commentedBy": "Erik Williams, M.D.", "commentedDts": "2022_07_05T20:38:56.000Z", "text": "This assay is not validated to identify chromosome_level cytogenetic aberrations. However, manual review of the copy_number profile suggests loss on chromosomes 19p and 22q. These findings could be confirmed by ancillary orthogonal cytogenetics testing, if clinically indicated (PMID: 34618539)."}}, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain meningioma", "flowcell_analysis": "2000022297", "gender": "female", "pathology_diagnosis": "Atypical meningioma", "percent_tumor_nuclei": "20", "pipeline_version": "v3.11.0", "purity_assessment": "52.8", "specimen": "ORD_1398056_01*US1343001.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1398056_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "892.6", "name": "SQ_US1343001.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4618", "cds_effect": "398G>T", "depth": "1230", "equivocal": "false", "functional_effect": "missense", "gene": "TIPARP", "percent_reads": "46.18", "position": "chr3:156395884", "protein_effect": "R133L", "status": "unknown", "strand": "+", "transcript": "NM_015508", "dna_evidence": {"sample": "SQ_US1343001.01_1"}}, {"allele_fraction": "0.4679", "cds_effect": "685T>A", "depth": "825", "equivocal": "false", "functional_effect": "missense", "gene": "MYD88", "percent_reads": "46.79", "position": "chr3:38182249", "protein_effect": "C229S", "status": "unknown", "strand": "+", "transcript": "NM_002468", "dna_evidence": {"sample": "SQ_US1343001.01_1"}}, {"allele_fraction": "0.4789", "cds_effect": "2545G>A", "depth": "641", "equivocal": "false", "functional_effect": "missense", "gene": "AXIN1", "percent_reads": "47.89", "position": "chr16:338166", "protein_effect": "V849I", "status": "unknown", "strand": "_", "transcript": "NM_003502", "dna_evidence": {"sample": "SQ_US1343001.01_1"}}, {"allele_fraction": "0.4651", "cds_effect": "1370_1372delAGG", "depth": "744", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "DAXX", "percent_reads": "46.51", "position": "chr6:33287880", "protein_effect": "E457del", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1343001.01_1"}}, {"allele_fraction": "0.4738", "cds_effect": "197C>T", "depth": "650", "equivocal": "false", "functional_effect": "missense", "gene": "CUL4A", "percent_reads": "47.38", "position": "chr13:113883818", "protein_effect": "T66M", "status": "unknown", "strand": "+", "transcript": "NM_003589", "dna_evidence": {"sample": "SQ_US1343001.01_1"}}, {"allele_fraction": "0.3121", "cds_effect": "1400T>C", "depth": "314", "equivocal": "false", "functional_effect": "missense", "gene": "DOT1L", "percent_reads": "31.21", "position": "chr19:2211146", "protein_effect": "V467A", "status": "unknown", "strand": "+", "transcript": "NM_032482", "dna_evidence": {"sample": "SQ_US1343001.01_1"}}, {"allele_fraction": "0.4696", "cds_effect": "1442G>A", "depth": "724", "equivocal": "false", "functional_effect": "missense", "gene": "BRIP1", "percent_reads": "46.96", "position": "chr17:59870989", "protein_effect": "G481D", "status": "unknown", "strand": "_", "transcript": "NM_032043", "dna_evidence": {"sample": "SQ_US1343001.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}